Added 13 days ago Drug news
Bristol-Myers Squibb Company announced the FDA has approved a supplemental Biologics License Application (sBLA) updating the Opdivo (nivolumab) dosing schedule...
Added 24 days ago Drug news
CHMP negative against Sutent for the adjuvant treatment of adult patients at a high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.- Pfizer.
Pfizer Inc.announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A
Watch video highlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.
The European Association of Urology (EAU) Renal Cell Cancer (RCC) Guidelines Panel has compiled these clinical guidelines to provide urologists...
Added 2 years ago
The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best...
Added 3 years ago
High-risk, localized renal cancer is associated with recurrence rates of up to 75% at 10 years. The outcomes of patients at this disease stage depend on optimal patient stratification, surgical management and systemic therapy selection.
Added 2 months ago
Immunotherapy has been used in localized urothelial carcinoma for decades, especially in the treatment of superficial disease, in which instillation of BCG is a commonly used treatment option.
Added 2 months ago
Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.
Objective: To describe the management strategies and outcomes of patients with renal medullary carcinoma (RMC) and characterise predictors of overall survival (OS).
Added 2 months ago
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma [IMmotion151]
This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC)...
Added 3 months ago
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.
Added 4 years ago
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003...
Added 4 months ago
Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more
Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.